Clinical Trial Update: Phase 2 Multi-center Randomized Study to the Efficacy and Safety of AK105 Combined With Anrotinib Hydrochloride in Patients With Recurrent/Refractory Classical Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 multi-center randomized study evaluating AK105 in combination with Anrotinib Hydrochloride for recurrent/refractory classical Hodgkin's lymphoma is curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classical Hodgkin Lymphoma

Drugs mentioned

• AK105 (anti-PD-1 monoclonal antibody)
• Anrotinib Hydrochloride (Anrotinib)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Recurrent/Refractory Classical Hodgkin's Lymphoma | Phase 2 | Status: ENROLLING_BY_INVITATION